Exagen to Announce Second Quarter 2024 Results on August 5, 2024
Exagen Inc. (Nasdaq: XGN), a leading autoimmune testing provider, has announced it will release its second quarter 2024 financial results on August 5, 2024, before the market opens. The company will host a conference call at 8:30 AM ET on the same day, featuring President and CEO John Aballi and CFO Kamal Adawi.
Interested parties can join the call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). A webcast link will be available on Exagen's investor relations website. A replay of the call will be accessible until August 19, 2024, via phone and webcast recording.
Exagen Inc. (Nasdaq: XGN), un fornitore leader di test autoimmune, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 il 5 agosto 2024, prima dell'apertura del mercato. L'azienda ospiterà una chiamata in conferenza alle 8:30 AM ET lo stesso giorno, con il Presidente e CEO John Aballi e il CFO Kamal Adawi.
Le parti interessate possono partecipare alla chiamata componendo il numero (201) 389-0918 (U.S.) o (877) 407-0890 (internazionale). Un link per la trasmissione sarà disponibile sul sito web delle relazioni con gli investitori di Exagen. Una registrazione della chiamata sarà accessibile fino al 19 agosto 2024, tramite telefono e registrazione della trasmissione.
Exagen Inc. (Nasdaq: XGN), un proveedor líder de pruebas autoinmunes, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 5 de agosto de 2024, antes de la apertura del mercado. La compañía realizará una conferencia telefónica a las 8:30 AM ET el mismo día, con el Presidente y CEO John Aballi y el CFO Kamal Adawi.
Las partes interesadas pueden unirse a la llamada marcando el número (201) 389-0918 (EE.UU.) o (877) 407-0890 (internacional). Un enlace para la transmisión estará disponible en el sitio web de relaciones con inversores de Exagen. Una repetición de la llamada será accesible hasta el 19 de agosto de 2024, a través de grabación telefónica y webcast.
Exagen Inc. (Nasdaq: XGN), 선도적인 자가면역 검사 제공업체가 2024년 2분기 재무 결과를 2024년 8월 5일, 시장 개장 전에 발표한다고 발표했습니다. 회사는 같은 날 오전 8시 30분 ET에 회의 전화를 주최하며, 존 아발리(CEO)와 카말 아다위(CFO)가 참석합니다.
관심 있는 분들은 (201) 389-0918 (미국) 또는 (877) 407-0890 (국제전화)로 전화를 걸어 참여할 수 있습니다. 웹캐스트 링크는 Exagen의 투자자 관계 웹사이트에서 제공됩니다. 통화 기록은 2024년 8월 19일까지 전화 및 웹캐스트 녹음을 통해 접근할 수 있습니다.
Exagen Inc. (Nasdaq: XGN), un fournisseur leader de tests auto-immuns, a annoncé qu'il publiera ses résultats financiers du deuxième trimestre 2024 le 5 août 2024, avant l'ouverture du marché. La société organisera une conférence téléphonique à 8h30 ET le même jour, avec le Président et PDG John Aballi et le CFO Kamal Adawi.
Les parties intéressées peuvent participer à l'appel en composant le (201) 389-0918 (États-Unis) ou le (877) 407-0890 (international). Un lien pour le webinaire sera disponible sur le site des relations avec les investisseurs d'Exagen. Un enregistrement de l'appel sera accessible jusqu'au 19 août 2024, par téléphone et par enregistrement de webinaire.
Exagen Inc. (Nasdaq: XGN), ein führender Anbieter von Autoimmun-Tests, hat angekündigt, dass die Finanzergebnisse für das zweite Quartal 2024 am 5. August 2024, vor Markteröffnung veröffentlicht werden. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz veranstalten, an der der Präsident und CEO John Aballi sowie der CFO Kamal Adawi teilnehmen.
Interessierte können sich unter (201) 389-0918 (USA) oder (877) 407-0890 (international) in die Konferenz einwählen. Ein Webcast-Link wird auf der Website der Investor Relations von Exagen verfügbar sein. Eine Aufzeichnung des Gesprächs ist bis zum 19. August 2024 über Telefon und Webcast verfügbar.
- None.
- None.
CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before the market opens on Monday, August 5, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT).
Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.
A replay of the conference call will be available until Monday, August 19, 2024, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13747595. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.
About Exagen Inc.
Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.
For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).
Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525
FAQ
When will Exagen (XGN) release its Q2 2024 financial results?
What time is Exagen's (XGN) Q2 2024 earnings conference call?
How can investors access Exagen's (XGN) Q2 2024 earnings call?
Until when will the replay of Exagen's (XGN) Q2 2024 earnings call be available?
